Fred Lublin from Mount Sinai Medical Center: Why Relapses Matter in Multiple Sclerosis Care

Video

With a lot of the attention in multiple sclerosis care turning to finding treatments for progressive forms of the disease those who suffer relapses are in some ways being left in the shadows of treatment discoveries and care.

With a lot of the attention in multiple sclerosis care turning to finding treatments for progressive forms of the disease those who suffer relapses are in some ways being left in the shadows of treatment discoveries and care.

Fred Lublin, MD, from Mount Sinai Medical Center gave one of the prominent talks during the annual meeting of the Consortium of Multiple Sclerosis Centers discussing why it is important to not lose sight of treating relapses today. With 14 medications now approved for relapsing remitting multiple sclerosis Lublin said doctors can help their patients manage their likelihood of relapse but still must keep an eye on their care to ensure their condition does not get worse over time.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.